ELL 12

Drug Profile

ELL 12

Alternative Names: edelfosine-liposomal; liposomal edelfosine; TLC ELL 12

Latest Information Update: 02 May 2007

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Elan Corporation
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 02 May 2007 Discontinued - Phase-I for Cancer in USA (unspecified route)
  • 24 Jan 2002 A clinical study has been added to the Cancer therapeutic trials, pharmacokinetics and adverse events sections
  • 31 May 2000 The Liposome Company has been acquired by Elan Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top